Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials

Cren, Pierre-Yves; Lebellec, Loïc; Ryckewaert, Thomas; Penel, Nicolas

Type de document :

Article dans une revue scientifique: Article de synthèse/Review paper

DOI :

10.3389/fonc.2020.594445

PMID :

33330082

URL permanente :

http://hdl.handle.net/20.500.12210/90471

Titre :

Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials

Auteur(s) :

Cren, Pierre-Yves [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Lebellec, Loïc [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Ryckewaert, Thomas [Auteur]
Département d'oncologie médicale
Penel, Nicolas [Auteur]

METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Titre de la revue :

Frontiers of Radiation Therapy and Oncology

Nom court de la revue :

Front. Oncol.

Numéro :

Date de publication :

2020-12-26

ISSN :

2234-943X

Mot(s)-clé(s) en anglais :

Choi criteria
clinical trial
multikinase inhibitor
non-adipocytic soft tissue sarcoma
sarcoma

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

We reviewed all fully published clinical trials assessing anti-angiogenic agents in sarcoma patients (last issue, January 13, 2020). Anti-angiogenic macromolecules (e.g., bevacizumab or ombrabulin) provide disappointing ...
Lire la suite >We reviewed all fully published clinical trials assessing anti-angiogenic agents in sarcoma patients (last issue, January 13, 2020). Anti-angiogenic macromolecules (e.g., bevacizumab or ombrabulin) provide disappointing results. Many multikinase inhibitors have been assessed with non-randomized phase II trials with limited samples and without stratification according to histological subtypes, therefore interpretation of such trials is very challenging. On the contrary, pazopanib, regorafenib, and sorafenib have been assessed using double-blind placebo-controlled randomized phase II or phase III trials. Compared to placebo, sorafenib demonstrates activity in desmoid-type fibromatosis patients. Based on results of phase 3 trial, pazopanib had obtained approval for treatment of pretreated non-adipocytic soft tissue sarcoma. Regorafenib is currently assessed in several clinical settings and provides significant improvement of progression-free survival in pre-treated non-adipocytic soft tissue sarcoma and in advanced pretreated osteosarcoma. Multikinase inhibitors are a breakthrough in sarcoma management. Many trials are ongoing. Nevertheless, predictive factors are still missing.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2023-11-15T07:33:05Z
2023-12-13T10:50:30Z

Fichiers

fonc-10-594445.pdf
Non spécifié
Accès libre
Accéder au document

Ce document est diffusé sous licence Attribution 3.0 United States

Numéro de version	Lien	Date de modification
2	20.500.12210/90471*	2023-12-13T10:46:46Z
1	20.500.12210/90471.1	2023-11-15T07:33:05Z

Anti-Angiogenic Agents in Management of ...

BibTeX

CSV

Excel

RIS

Fichiers

Historique des modifications

Anti-Angiogenic Agents in Management of ... BibTeX CSV Excel RIS

Fichiers

Historique des modifications

Anti-Angiogenic Agents in Management of ...

BibTeX

CSV

Excel

RIS